Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Surgery ; 164(3): 473-481, 2018 09.
Article de Anglais | MEDLINE | ID: mdl-29884476

RÉSUMÉ

BACKGROUND: Autologous hepatocyte transplantation after ex vivo gene therapy is an alternative to liver transplantation for metabolic liver disease. Here we evaluate ex vivo gene therapy followed by transplantation of single-cell or spheroid hepatocytes. METHODS: Pig and mouse hepatocytes were isolated, labeled with zirconium-89 and returned to the liver as single cells or spheroids. Biodistribution was evaluated through positron emission tomography-computed tomography. Fumarylacetoacetate hydrolase-deficient pig hepatocytes were isolated and transduced with a lentiviral vector containing the Fah gene. Animals received portal vein infusion of single-cell or spheroid autologous hepatocytes after ex vivo gene delivery. Portal pressures were measured and ultrasound was used to evaluate for thrombus. Differences in engraftment and expansion of ex vivo corrected single-cell or spheroid hepatocytes were followed through histologic analysis and animals' ability to thrive off 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione. RESULTS: Positron emission tomography-computed tomography imaging showed spheroid hepatocytes with increased heterogeneity in biodistribution as compared with single cells, which spread more uniformly throughout the liver. Animals receiving spheroids experienced higher mean changes in portal pressure than animals receiving single cells (P < .01). Additionally, two animals from the spheroid group developed portal vein thrombi that required systemic anticoagulation. Immunohistochemical analysis of spheroid- and single-cell-transplanted animals showed similar engraftment and expansion rates of fumarylacetoacetate hydrolase-positive hepatocytes in the liver, correlating with similar weight stabilization curves. CONCLUSION: Ex vivo gene correction of autologous hepatocytes in fumarylacetoacetate hydrolase-deficient pigs can be performed using hepatocyte spheroids or single-cell hepatocytes, with spheroids showing a more heterogeneous distribution within the liver and higher risks for portal vein thrombosis and increased portal pressures.


Sujet(s)
Transplantation cellulaire/méthodes , Thérapie génétique , Hépatocytes/transplantation , Sphéroïdes de cellules/transplantation , Tyrosinémies/thérapie , Animaux , Modèles animaux de maladie humaine , Femelle , Mâle , Souris , Suidae , Tyrosinémies/imagerie diagnostique , Tyrosinémies/anatomopathologie
2.
J Pediatr Endocrinol Metab ; 29(10): 1151-1157, 2016 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-27682708

RÉSUMÉ

BACKGROUND: Hereditary tyrosinemia type 1 (HT1) is a rare, inborn error of tyrosine metabolism. It is a fatal disorder without treatment. Early treatment may prevent acute liver failure, renal dysfunction, liver cirrhosis, hepatocellular carcinoma (HCC) and improves survival. The aim of the present study is to describe the clinical, biochemical, imaging and follow-up of seven patients with HT1 and to define the consequences of the late and interrupted treatment. METHODS: A retrospective study was carried out with seven HT1 patients. RESULTS: The median age at onset of clinical symptoms was 11.2 months (range, 3-28 months) and the median age at diagnosis was 22 months (range, 6-58 months). Liver enzymes and coagulation parameters were back to normal in all symptomatic patients in about 2 weeks. Alfa-fetoprotein (AFP) levels were normalized within the first year of therapy. Hypoechoic nodule formation was detected in two of the seven patients despite drug treatment without an increase of AFP and any dysplastic changes in the biopsies. One patient died due to metastatic HCC because of the late diagnosis and the poor compliance of the follow-up. CONCLUSIONS: This study showed once again that adherence to the treatment and a follow-up schedule of the patients are very important. Also it should not be forgotten that nodule formation can occur despite nitisinone treatment without an increase of AFP. Despite nitisinone treatment, HT1 patients still carry the risk of HCC. HCC must be detected before metastasis to other organs otherwise, patients may lose the chance for liver transplantation.


Sujet(s)
Cyclohexanones/usage thérapeutique , Antienzymes/usage thérapeutique , Nitro-benzoates/usage thérapeutique , Tyrosinémies/traitement médicamenteux , Marqueurs biologiques/analyse , Enfant , Enfant d'âge préscolaire , Échocardiographie , Femelle , Chromatographie gazeuse-spectrométrie de masse , Humains , Nourrisson , Imagerie par résonance magnétique , Mâle , Études rétrospectives , Résultat thérapeutique , Tyrosinémies/imagerie diagnostique , Tyrosinémies/anatomopathologie , Échographie
3.
Acta Radiol ; 46(6): 618-20, 2005 Oct.
Article de Anglais | MEDLINE | ID: mdl-16334844

RÉSUMÉ

A 3.5-year-old girl with tyrosinemia is reported. A computed tomography scan of the abdomen revealed multiple hepatic nodules. Brain magnetic resonance imaging revealed bilateral high-signal changes confined to the globus pallidus on T2-weighted images. Globus pallidus lesions likely represented neuropathologic changes such as astocytosis, delayed myelination, and status spongiosus (myelin splitting and vacuolation).


Sujet(s)
Encéphalopathies/diagnostic , Imagerie par résonance magnétique , Tyrosinémies/complications , 4-hydroxyphenylpyruvate dioxygenase/déficit , Enfant d'âge préscolaire , Maladies démyélinisantes/diagnostic , Femelle , Gliose/diagnostic , Globus pallidus/anatomopathologie , Humains , Gaine de myéline/anatomopathologie , Radiographie , Tyrosinémies/imagerie diagnostique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...